Forum: Risks and rewards of gene editing
By Marcy Darnovsky,
Issues in Science and Technology
| 07. 31. 2020
In this interview as in past public comments, Jennifer Doudna opens the door to using the CRISPR platform she helped develop in the service of a hugely controversial enterprise: altering the genomes and traits of future children and subsequent generations. She does so under the banner of responsible science and policy. But as with similar comments by supporters of heritable genome manipulations, her responses shed little light on what criteria would constitute “responsible use,” how irresponsible uses could be avoided, and how this immensely consequential decision might be made in an open and democratically responsible way.
To be sure, Doudna notes that “the main challenge in embryo editing is not scientific … but rather ethical,” and raises important questions about the feasibility of consent by future generations, the difficulty of distinguishing between medical applications and enhancements, and the harm that eradicating genetic conditions might bring to people living with those conditions. But she gives no hint about how these challenges could be met. Tellingly, she fails to mention the broader social justice alarms about heritable genome editing: that the accumulation...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...